Back to Newsroom

Alder BioPharmaceuticals Appoints Paul R. Carter to Board of Directors

BOTHELL, Wash., Sept.30, 2015 – Alder BioPharmaceuticals, Inc. (“Alder”) (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced the appointment of Paul R. Carter to its Board of Directors, effective immediately. Mr. Carter currently serves as Executive Vice President, Commercial Operations at Gilead Sciences, Inc.

Click here to read more